HER-2/AKT expression in upper urinary tract urothelial carcinoma: Prognostic implications

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2439-2445

  Izquierdo, Laura ^a   Truan, David ^b   Mengual, Lourdes ^a   Mallofré, Carmen ^a   Alcaraz, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

AKT; HER 2; Immunohistochemistry; Upper urinary tract; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; UPPER URINARY TRACT UROTHELIAL CARCINOMA; URINARY TRACT CARCINOMA;

AGED; AGED, 80 AND OVER; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 77955079033     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Munoz JJ and Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 164: 1523-1525, 2000.
2. Marin-Aguilera M, Mengual L, Ribal MJ, Musquera M, Ars E, Villavicencio H, Algaba F and Alcaraz A: Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 51: 409-415, 2007.
3. Huben RP, Mounzer AM and Murphy GP: Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 62: 2016-2020, 1988.
4. Holbro T and Hynes NE: ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217, 2004. (Pubitemid 38263839)
5. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
6. Bianco R, Gelardi T, Damiano V, Ciardiello F and Tortora G: Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 39: 1416-1431, 2007.
7. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S and van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99: 341-349, 2008.
8. Mass RD: The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58: 932-940, 2004.
9. Tsai YS, Tzai TS, Chow NH and Wu CL: Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 66: 1197-1202, 2005.
10. Gardmark T, Wester K, De la TM, Carlsson J and Malmstrom PU: Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 95: 982-986, 2005. (Pubitemid 40655692)
11. Itoh N, Semba S, Ito M, Takeda H, Kawata S and Yamakawa M: Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94: 3127-3134, 2002.
12. Mostofi, Sorbin LH, and Torloni H: Histological Typing of Urinary Bladder Tumors. International Histological Classification of Tumors. Geneva, Switzerland, World Health Organization, 1973.
13. Sobin LH and Wittekind Ch: TNM Classification of Malignant Tumours. New York, Wiley, 2002.
14. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M and Lohrs U: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354-363, 2001.
15. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS and Figlin RA: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109: 2257-2267, 2007.
16. Wester K, Sjostrom A, De la TM, Carlsson J and Malmstrom PU: HER-2 - a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 41: 282-288, 2002.
17. Jalali Nadoushan MR, Taheri T, Jouian N and Zaeri F: Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urol J 4: 151-154, 2007.
18. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr and Grignon DJ: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7: 2440-2447, 2001.
19. Wulfing C, von Struensee D, Bierer S, Bogemann M, Hertle L and Eltze E: Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy. Aktuelle Urol 36: 423-429, 2005.
20. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D and Ghani F: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: R436-R443, 2005.
21. Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL and Kolbitsch C: Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 2008.